Company intelligence / Profile preview
Allergy Therapeutics PLC
Worthing, West Sussex, United Kingdomallergytherapeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Currently conducting Phase I/IIa PROTECT trial for VLP Peanut vaccine with Part A completed in April 2023 showing no safety signals in healthy volunteers. Part B is ongoing at 10 US clinical sites with 36 peanut-allergic patients receiving three escalating doses. The company also has a Phase 3 ragweed pollen hypersensitivity treatment in development.
- Therapeutic areas
- OncologyImmunologyInfectious Diseases
- Modalities
- VaccinesSubcutaneous immunotherapyVirus-like particle (VLP) technologyAdjuvant systems
- Industry
- Biotech
02
Drug pipeline
31 assets30 more assets in the full pipeline.
Beyond the preview
Go deeper on Allergy Therapeutics PLC.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Allergy Therapeutics PLC.